

ORIGINAL ARTICLE

ANTIFUNGAL SUSCEPTIBILITY TESTING AND GENOTYPING CHARACTERIZATION OF *Cryptococcus neoformans* AND *gattii* ISOLATES FROM HIV-INFECTED PATIENTS OF RIBEIRÃO PRETO, SÃO PAULO, BRAZIL

Thais Pandini FIGUEIREDO(1,9), Rosymar Coutinho de LUCAS(2,3) Rodrigo Anselmo CAZZANIGA(4), Carolina Nunes FRANÇA(5,6), Fernando SEGATO(7), Rafael TAGLIALEGNA(8) & Claudia Maria Leite MAFFEI(8)

SUMMARY

Cryptococcosis is a leading invasive fungal infection in immunocompromised patients. Considering the high prevalence and severity of these infections in immunocompromised patients attended at HC-FMRP-USP, the present research aimed to characterize the clinical isolates of *Cryptococcus* strains by biochemical and molecular methods and evaluate antifungal susceptibility of clinical isolates. Fifty isolates from 32 HIV-positive patients were obtained at HC-FMRP-USP. Most of the isolates (78.1%) were identified as *C. neoformans*, and 100% of *C. neoformans* and *C. gattii* strains were susceptible to amphotericin B, ketoconazole and fluconazole. All isolates were classified as serotype A (*grubii* variety) by PCR and most of them were characterized in mating type MAT α . PCR analysis of specific M13 microsatellite sequence revealed that VNI type was predominant among *C. neoformans*, while VGII was predominant among *C. gattii*. The strains did not show a significant resistance to the antifungals tested, and Canavanine-Glycine-Bromthymol Blue Agar (CGB) proved to be a reliable test presenting a good correlation with the molecular characterization. *C. neoformans* isolated from disseminated infections in the same patient showed molecular identity when different anatomical sites were compared; besides, the studied strains did not present a significant increase in resistance to antifungal agents. In addition, the homogeneity of the molecular types and detection of the mating types suggested a low possibility of crossing among the strains.

KEYWORDS: *Cryptococcus neoformans*; Serotyping; Genotyping; Fingerprinting; Antifungal agents; Mating type; HIV-patients.

INTRODUCTION

Cryptococcus sp is a saprophyte encapsulated yeast that exhibits single or multiple asynchronous buds, and has five serotypes, A, B, C, D and AD. It is subdivided into two varieties known as *C. grubii* (serotype A) and *C. neoformans* (serotypes D and AD), while the serotypes B and C are grouped into *C. gattii* species¹⁻³. However, there is a new nomenclature classifying *C. neoformans* as the strains considered var. *grubii* (serotype A) and *C. deneoformans* as the var. *neoformans* (serotype D). In addition, *C. gattii* will comprise five species: *C. gattii*, *C. bacillisporus*, *C. deuterogattii*, *C. tetragattii* and *C. decagattii*^{4,5}.

Representatives of this genus grow at 37 °C, hydrolyze starch, produce urease and do not ferment lactose⁶. Cryptococcal infections

occur worldwide in undefined endemic areas. However, the environmental serotype distribution shows some differences, presenting *C. gattii* as the prevalent species in tropical and subtropical areas⁷⁻⁹.

Routinely, *C. neoformans* and *C. gattii* cultures are distinguished in CGB-Agar, an enriched medium, which inhibits *C. neoformans* growth and favors *C. gattii* development. The color change from yellow-green to blue-cobalt indicates serotypes B and C¹⁰.

Another important identification method for this species is the sexual mating type analysis. The mating locus MAT of *C. neoformans* serotype A and D is unique. It is characterized by different regions with very similar structures and functions, which can be also found in other fungi. MAT locus has an average size of 100 Kb, comprising more than 20 genes,

(1) Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica. 14049-900 Ribeirão Preto, SP, Brazil. E-mail: thais.pandini@gmail.com
(2) Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Bioquímica. 14049-900 Ribeirão Preto, SP, Brazil. E-mail: rosymar_lucas@hotmail.com
(3) Universidade de São Paulo, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Departamento de Biologia. 14040-901 Ribeirão Preto, SP, Brazil. E-mail: rosymar_lucas@hotmail.com
(4) Universidade Federal de Sergipe, Departamento de Morfologia. 49100-000, SE, Brazil. E-mail: cazzaniga.rodrigo@gmail.com
(5) Universidade de Santo Amaro, UNISA, Pós Graduação em Ciências da Saúde, São Paulo, SP, Brazil. E-mail: carolufscar24@gmail.com
(6) Universidade Federal de São Paulo, UNIFESP, Departamento de Medicina, São Paulo, SP, Brazil. E-mail: carolufscar24@gmail.com
(7) Universidade de São Paulo, Escola de Engenharia de Lorena, Departamento de Biotecnologia. 12602-810, Lorena, SP, Brazil. E-mail: segatof@icloud.com
(8) Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Biologia Celular, Molecular e Bioagentes Patogênicos. 14049-900 Ribeirão Preto, SP, Brazil. E-mails: rafaeltaglialeгна@hotmail.com; cmlmaffe@fmrp.usp.br
(9) Universidade Federal de Ouro Preto, Núcleo de Inovação Tecnológica, 35400-000 Ouro Preto, MG, Brazil. E-mail: thais.pandini@gmail.com
Correspondence to: Rosymar Coutinho de Lucas, Av. Bandeirantes 3900 Monte Alegre 14040-901, Ribeirão Preto, SP, Brasil. Tel: + 55 16 3602 3229. E-mail: rosellucas@usp.br

some being present in both alleles MATa and MAT α , and other genes present in only one of these alleles¹¹⁻¹⁵. Although diploid or aneuploidy strains are rare, they have already been isolated in nature^{16,17}.

In *C. gattii*, it is only possible to determine the sexual type using oligonucleotides flanking the genes MF α 1 and MF α 2. On the other hand, the serotype B/C is identified by PCR using a primer pair specific for *C. gattii* superoxide dismutase gene¹⁸⁻¹⁹.

Serotypes A and D, mating type α , are the most common variety causing infections in humans. Although studies with serotypes A, D, AD, B and C have not demonstrated differences in the susceptibility to antifungal agents, the higher incidence of serotypes A, D and AD in HIV-infected patients have suggested a pattern behavior that is demonstrated by clinical and epidemiological studies²⁰⁻²³.

C. neoformans is the major cause of cryptococcosis affecting millions of people worldwide. In patients with the acquired immunodeficiency syndrome (AIDS) or immunosuppressive conditions, such as organ transplantation or submitted to chemotherapy treatment, cryptococcosis represents the most common fungal infection. During the disease, various strategies are employed to treat these infections, including amphotericin B alone or in combination with 5-flucytosine and azoles, as fluconazole, itraconazole or voriconazole, which are the standard reference drugs nowadays^{24,25}. Considering the high frequency of cryptococcosis in HIV-infected patients attended at the University Hospital of Ribeirão Preto Medical School, University of Sao Paulo (HC-FMRP-USP), the present investigation aimed to characterize the clinical isolates of *Cryptococcus* strains by biochemical and molecular methods. The molecular typing, serotyping and mating type identification by molecular biology techniques were used to identify and distinguish the isolates. In addition, the strains were characterized regarding the sensitivity profile to the antifungal agents, amphotericin B, ketoconazole, itraconazole, fluconazole and 5-fluorocytosine.

MATERIAL AND METHODS

Cryptococcus isolates

Fifty isolates collected from 32 patients at HC-FMRP-USP and belonging to the *Cryptococcus* collection from the Mycology Laboratory - Department of Cell and Molecular Biology, and Pathogenic Bioagents (FMRP-USP) were selected for phenotypic and genotypic studies. The strains were maintained in Sabouraud Dextrose Agar medium (SDA) at room temperature. The strains were previously identified as belonging to the genus *Cryptococcus* using the classical identification tests such as capsule observation using Indian ink stain and biochemical tests, such as urea degradation and sugars assimilation analysis²⁶.

The isolates were divided into three groups as follow: Group I – strains isolated from different patients; Group II – strains isolated from the same patient at the same period, in different anatomical sites; and Group III – strains isolated from the same patient at different periods.

Biochemical characterization of *Cryptococcus*

The isolates were subcultured in CGB-Agar, pH 5.6, in which the fungi culture presents the typical greenish yellow color according to

Kwon-Chung *et al.*¹⁰. Isolates were incubated at 37 °C for 48 hours and the reading was performed according to the growth characteristic in this medium: the maintenance of the original medium color is an indication of *C. neoformans* (serotypes A, D, and AD), while the change to blue-cobalt shade characterizes *C. gattii* (serotypes B and C). Simultaneously, *Cryptococcus* reference strains were used as experimental controls: A (CDC 9759), B (ATCC 32269), C (ATCC 24066), and D (ATCC 28958).

DNA isolation

The genomic DNA extraction method was based on the methodology described by Bolano *et al.*²⁷.

Determination of mating type and serotype

The amplification reactions for sexual type and serotype characterization were performed with Taq DNA Polymerase (Fermentas, Thermo Fisher Scientific, Waltham, Massachusetts, USA), according to the manufacturer's instructions in a PTC-200 thermal cycler (MJ Research, GMI Inc., Ramsey, Minnesota, USA), and it was establish 32 cycles for the PCR. Table 1 presents the primer sequences, annealing temperatures and PCR product sizes according to each pair of pairs^{28,17}. The amplification products were submitted to electrophoresis on 1% agarose gels in 1X TAE (Tris-Acetate-EDTA) at 75 volts for 2 hours. Gels were stained with ethidium bromide, visualized under UV light and the images were captured by the Alpha-Innotech Image System (Alpha-Innotech Corp., San Leandro, CA, USA)²⁹.

PCR-fingerprinting

The molecular typing of *Cryptococcus* isolates was performed according to the methodology described by Meyer³⁰⁻³², which is based on random amplification of DNA fragments generated by primers recognizing specific minisatellite sequences, allowing a molecular classification defined as VNI, VNII, and VNIII VNIV to *C. neoformans*, and VGI, VGII, and VGIII to *C. gattii*. The primers were M13 (5'-GAGGGTGGCGTTCT-3') and (GACA)₄³¹. All reactions were performed in a final volume of 50 μ L containing 100 ng of genomic DNA, 10 pmol of each primer, 2 mM of MgCl₂, 2.5 U of Taq DNA polymerase, 1x PCR Buffer and 10 mM of each dNTP. Amplification conditions were: initial denaturation step at 94 °C for 5 minutes, followed by 35 cycles: denaturation at 94 °C for 1 minute, annealing at 49 °C for 1 minute, extension at 72 °C for 1 minute, followed by a final extension at 72 °C for 10 minutes. The generated amplification products were submitted to electrophoresis on 1% agarose gels as previously described, and the interpretation of results was based on the number and size of the amplification products.

Antifungal susceptibility testing

The susceptibility of *C. neoformans*, *C. gattii* and the control strains to antifungal agents was determined by the microdilution plate method, with some modifications based on the protocol recommended by the National Committee for Clinical Laboratory Standards, document (CLSI M27-A2). The drugs used here were amphotericin B (Fungizon, Bristol-Myers-Squibb, Brazil), ketoconazole (Janssen Cilag, Brazil), itraconazole (Janssen Cilag, Brazil), fluconazole (Pfizer, Brazil) and 5-fluorocytosine (Roche, Brazil). The stock solution of

Table 1

Identification of primers, primer sequences, annealing temperature, molecular weight of amplification products to determine mating type and serotype and references

Primer name	Sequences “Forward and Reverse”	Annealing T°C	Product size (bp)	Reference
STE20aA	5'-TCCACTGGCAACCCTGCGGAG-3' 5'-ATCAGAGACAGAGAAGCAAGAC-3'	55	865	[28]
SXI2aD	5'-GGTCCGCACTTGGGTAAGTG -3' 5'-GGCGTAGACGGACGAGGCTC -3'	61	1420	Lin; Heitman, Personal Contact
SXI1αA	5'-GCTTGGCGTACGCTGTGG -3' 5'-GGCGTCGCTTGGTACGGGT -3'	55	1150	Lin; Heitman, Personal Contact
STE20αD	5'-GATTATCTCAGCAGCCACG-3' 5'-AAATCGGCTACGGCACGTC-3'	61	443	[28]
SOD1 B/C	5'-GATCCTCACGCCATTACG-3' 5'-GAATGATGCGCTTAGTTGGA-3'	52	1000	[20]
MFα1 – universal	5'-CTTCACTGCCATCTTACCA-3' 5'-GACACAAAGGGTCATGCCA-3'	57.5	101	[17]
MFa2–B/C	5'-ACACCGCCTGTTACAATGGAC-3' 5'-CAGCGTTGAAGATGGACTTT-3'	55	213	[18]

each drug was prepared with sterilized water for amphotericin B, fluconazole and 5-fluorocytosine, and DMSO (dimethyl sulfoxide) for ketoconazole and itraconazole, divided in aliquots in sterilized microcentrifuge tubes and stored at -80 °C until used. Two serial dilutions of each antifungal agent were prepared with RPMI 1640 medium (Sigma Chemical Co., Saint Louis, Missouri, USA) with L-glutamine and without sodium bicarbonate, and buffered to pH 7.0 with 0.165 M MOPS (morpholinopropanesulfonic acid). The final concentrations ranged from 0.0312 to 16 µg/mL for amphotericin B; 0.0312 to 16 µg/mL for itraconazole; 0.0625 to 32 µg/mL ketoconazole; 0.25 to 128 µg/mL for 5-fluorocytosine and 0.25 to 128 µg/mL fluconazole. The microdilution assay was performed in 96-well microdilution plates. Results were visually evaluated after 72 hours of incubation for *C. neoformans* isolates and 48 hours for *Candida parapsilosis* standard sample. In order to validate the test, the standard sample used in all reactions showed minimal inhibitory concentrations (MIC) for each antifungal, within known ranges. The MIC determined for ketoconazole, itraconazole, fluconazole and 5-fluorocytosine corresponded to the concentration that inhibited more than 50% of the fungal growth, compared with the positive control, and for amphotericin B the MIC was considered the concentration showing 100% of growth inhibition. Isolates were considered susceptible or resistant to the tested antifungal agents in accordance to breakpoint values defined by Clinical and Laboratory Standards Institute (CLSI), 2002^{33,34}.

RESULTS

The strains collected from 32 HIV-positive patients comprised 50 isolates, from which 78.1% were phenotypically identified as *C. neoformans* and 21.9% corresponded to *C. gattii* species according to biochemical tests. Serotype and sexual type (mating type) characterizations were simultaneously performed by PCR, showing that every sample from group I was classified as MaTα type. From

the seven isolates biochemically identified as *C. gattii*, only one sample (number 46) was positive for the MFa2 primer pair, which is specific for *C. gattii* sexual type “a”. The amplifications for MFα1 and MFa2 showed that this sample is diploid α/a, serotype B/C. The remaining *C. gattii* isolates were compatible with serotype B/C which are sexual type α. The presence of bands for the gene SXI1Aα in the tested isolates, compared with bands for the genes STE20Dα, STE20Aa and SXI2Da in the positive controls showed that all isolates in group I were classified as serotype A and mating type α, which is characteristic of *C. neoformans* variety *grubbi* (Fig. 1).




Fig. 1 - Group I *Cryptococcus* isolates. Agarose gel of PCR reactions used for determination of sexual type and serotype. PCR products were obtained using specific primer pairs (MFα1, MFa2 B/C, SOD1 B/C, Aα, Dα, Aa and Da). Molecular weight markers are shown on the left side; the lane on the right side indicates the (+) control of each reaction. The remaining lanes represent the studied isolates, identified at the top of the figure by numbers.




Fig. 2 - Agarose gels showing sexual types and serotypes of *Cryptococcus* isolates. 2A (on the left) corresponds to Group II samples and 2B (on the right) to Group III samples. PCR products were obtained using specific primers (MF α 1, MF α 2 B/C, SOD1 B/C, A α , D α , A α and Da). The first lane on the left side shows the molecular weight markers; the right lane on the right side shows the (+) control of each reaction. The remaining lanes represent the studied isolates, identified at the top of the figure by numbers.

Using the same primers mentioned above, for the sexual typing and serotyping characterization, identical behavior was observed for the Groups II (strains isolated from the same patient in different anatomical sites) and III (strains isolated from the same patient at different periods of observation), all the isolates were characterized as MAT α serotype A variety *C. grubbi*. Indeed, amplification with the SOD1/BC primers was not observed, corroborating the expectations of our previous characterization using the CGB method (Fig. 2).

The technique with the specific microsatellite sequence M13, allowed the molecular typing of all the strains and revealed that the VNI molecular type predominated, occurring in 55% of the *C. neoformans* strains. Concerning *C. gattii* strains, the VGII molecular type was the most frequent, appearing in 71% of the strains (Table 2). Moreover, for almost all the patients that presented a new disease episode, even after one year without symptoms, the molecular typing results suggested an endogenous reactivation, due to the persistency of the original strain.

The *in vitro* sensitivity tests performed by microdilution assays showed that from all the studied groups, 100% of *C. neoformans* and *C. gattii* strains were susceptible to amphotericin B, ketoconazole and fluconazole. *C. neoformans* strains presented a dose-dependent sensitivity profile to the antifungal 5-fluorocytosine. A high frequency of MIC values for itraconazole was also observed, corresponding to a susceptible dose-dependent and resistance pattern (Table 3 and 4).

DISCUSSION

Cryptococcus is a cosmopolitan fungus, isolated from soil, animals and bird excrement. The mycosis caused by this fungus, cryptococcosis, is one of the main diseases affecting especially immunocompromised individuals. In this study, the species characterization of isolates from HIV-infected patients living in the city of Ribeirão Preto, state of São Paulo, Brazil, was performed by analyses of fungal growth in CGB-Agar and molecular characterization. There was a 100% agreement between these two methods for the species identification, showing that the CGB biochemical test is reliable and offers advantages because it is not expensive, is little laborious and provides fast results^{17,21,35,36}.

It was also observed that among the 32 patients, the majority of the isolates (78.1%) were identified as *C. neoformans*, and 21.9% were infected with *C. gattii*. In several studies in HIV patients, the isolation rate of *C. neoformans* is around 90%. Regarding *C. gattii*, overall rates of isolation from clinical material are around 11%, which is higher in immunocompetent patients than in patients with HIV. However, there is no definite explanation for this fact³⁷⁻⁴⁴. The high *C. gattii* rate found in this work can be explained by the proximity with its natural reservoirs or by the fact that HC-FMRP-USP is a reference center for the treatment of this pandemic infection, which may concentrate more exotic cases of cryptococcosis.

Table 2

Isolates of *Cryptococcus* species (*C. neoformans* or *C. gattii*) distributed according to the group (I, II, III), frequencies and molecular type

Group	n (%)	<i>C. neoformans</i> (%)	Molecular type (%)	<i>C. gattii</i> (%)	Molecular type (%)
I	20 (62.5)	13 (65.0)	VNI = 10 (77.0) VNII = 3 (23.0)	7 (35.0)	VGII = 5 (71.4) VGIII = 2 (28.6)
II	15 (21.9)	15 (100.0)	VNI = 13 (86.7) VNII = 2 (13.3)	0 (0)	0 (0)
III	15 (15.6)	15 (100.0)	VNI = 1 (6.7) VNII = 14 (93.3)	0 (0)	0 (0)
Total	50 (100.0)	43 (78.1)	VNI = 24 (55.8) VNII = 19 (44.2)	7 (21.9)	VGII = 5 (71.4) VGIII = 2 (28.6)

Table 3
Frequency of *Cryptococcus* isolates identified as *C. neoformans* or *C. gattii*, distributed in groups I/II or III, with respect to their susceptibility to the three antifungal agents* (susceptible, intermediate and resistant)

Antifungal	Susceptible		SDD		Resistant				
	<i>C. neoformans</i>	<i>C. gattii</i>	<i>C. neoformans</i>	<i>C. gattii</i>	<i>C. neoformans</i>	<i>C. gattii</i>			
Itraconazole	GI/II	2 (20%)	2 (29%)	GI/II	18 (80%)	5 (71%)	GI/II	0	0
	GIII	3 (20%)	-	GIII	9 (60%)	-	GIII	3 (20%)	-
Fluconazole	GI/II	20 (100%)	7 (100%)	GI/II	0	0	GI/II	0	0
	GIII	14 (93%)	-	GIII	1 (7%)	-	GIII	0	-
5-Fluocytosine	GI/II	17 (75%)	7 (100%)	GI/II	3 (15%)	0	GI/II	0	0
	GIII	13 (87%)	-	GIII	2 (13%)	-	GIII	0	-

GI/II = group I and II; GIII = group III; SDD = susceptible-dose-dependent; - = group III does not present any *C. gattii* isolates. * All the isolates were susceptible to Amphotericin B and Fluconazole.

Table 4
Susceptibility test of the samples to five antifungals, and distribution according to the group (I/II and III), breakpoint concentrations, MIC range, MIC 50 and MIC 90

Antifungal	Groups	Breakpoint concentrations	MIC range	MIC 50	MIC 90
Amphotericin B	GI/II	1.0	0.0156-8.0	0.125	0.5
	GIII			0.25	0.5
Ketoconazole	GI/II	4.0	0.0312-16.0	0.125	0.25
	GIII			0.25	0.5
Itraconazole	GI/II	0.125	0.0156-8.0	0.25	0.5
	GIII			1.0	1.0
Fluconazole	GI/II	8.0	0.125-64.0	2.0	2.0
	GIII			2.0	4.0
5-Fluorocytosine	GI/II	4.0	0.125-64.0	2.0	4.0
	GIII			2.0	4.0

GI/II = groups I and II; GIII = group III. Values are presented in µg/mL. NCCLS MIC breakpoint concentrations.

C. gattii was isolated only among patients from Group I, demonstrated by the positive amplification products of SOD1 sequence B/C. All of the groups (I, II and III) showed sexual type MAT α prevalence (MF α 1 gene recognition), which is consistent with reports of the literature for clinical isolates^{35,45}. Meanwhile, in this study, only one *C. gattii* isolate (number 46) was identified and was also recognized by specific primers for the gene MFa1-B/C, resulting in a 213 bp amplification product, thus characterizing the sample as a diploid (MATa / α). Reports on this behavior are rare, especially for serotypes B and C, since the occurrence of diploidy is preferably checked in the case of serotypes A, D and AD isolates (A α Da or AaD α)^{2,16}.

All the *C. neoformans* isolates (Groups I, II and III) were characterized as belonging to serotype A, MAT α , a characteristic frequently observed in the literature^{45,46}. For serotype A (*C. neoformans* var. *grubii*), Lengeler¹⁶ and Keller⁴⁷ suggested that MATa is becoming extinct, because these isolates are usually non fertile or because they belong to an ecological niche that has not yet been found. In the present study, the serotype D was not identified in any of the studied groups, regarding MATa or MAT α .

It is known that the mating type condition can influence the fungus virulence since there is a predominance of MAT α cells in these patients. Furthermore, these cells are more pathogenic in the murine model, although the MAT α type is also common in nature⁴⁸. Because of the mating gene *locus* that is not the same among MATa, MAT α alleles and serotypes, the molecular characterization is a safer identification method and requires the use of various combinations of primers to determine the serotype, as well as the corresponding species and sexual type. Therefore, this methodology is important since it can indicate differences in virulence and shows differences in the antifungal medical treatment responses. Besides, the knowledge of these variations is essential to understand the infection source, recurrence cases or reinfection and the host immune response^{49,50}.

In this study, the molecular typing was performed using RAPD-PCR with the specific microsatellite sequences M13 and (GACA)₄ according to the definition and molecular types standardization previously established by Meyer *et al.*³¹. Two *C. neoformans* molecular types were observed for the M13 specific primer, being the molecular type VNI the predominant, and for *C. gattii* two molecular types were detected, being the molecular

type VGII the most frequent. It is important to emphasize that the *C. neoformans* serotype A (var. *grubii*) identification was confirmed, since the VNI and VNII molecular types correspond precisely to this strain, corroborating previous data^{51,52}. It was possible to observe that with this analysis, four patients had recurrent episodes of cryptococcosis, and one patient was re-infected by a new *C. neoformans*⁵³⁻⁶⁰.

The MIC values observed for isolates from Groups I and II, regardless of the species, was consistent with the values reported in the literature, excepting for the values obtained for itraconazole^{7,40,61}. No difference was observed between the MIC values for *C. neoformans* and *C. gattii* regarding the five antifungal agents tested. They were all in agreement with MIC values reported by Sorrel³⁹, but in disagreement with those reported by Fernandes⁴⁰ that observed higher MIC values for *C. gattii*. For group III (patients with recurrent episodes of the disease) a discrepancy of MIC values was observed only for itraconazole, but for the other four drugs, MICs values indicated that 90% of the isolates had the MIC sensitivity profile defined for these drugs.

Amphotericin B alone or in combination with 5-fluorocytosine is the regimen of choice for the treatment of cryptococcal meningitis. This drug alone or the combination is used in the early stages of therapy and is associated with high toxicity. Fluconazole is primarily indicated for secondary prophylaxis of this disease, aiming to reduce the risk of infection recurrence in patients that still maintain the status of immunosuppression^{41,42}. Ketoconazole and itraconazole are not first-line drugs for the treatment of this disease in Brazil, however, they were included in this research only to investigate the strains behavior regarding these antifungals and to evaluate possible cross-resistance among azoles.

Based on the results obtained in this study, it was possible to conclude that the strains isolated from HIV-patients living in the city of Ribeirão Preto, a region that did not present a significant increase in resistance to the antifungal agents used in the clinical practice, and also that the biochemical test CGB-Agar is reliable given the good correlation between this method and the molecular characterization. Furthermore, the homogeneity of the molecular and mating types detected in these strains indicate a low probability of crossing among strains.

ACKNOWLEDGEMENTS

The authors are thankful for the technical support of Marly de Castro, for the valuable help with the molecular characterization of strains provided by Mateus Terceti and for the financial support from the Coordination for the Improvement of Higher Education Personnel, Brazil – (CAPES - Institutional Quota).

AUTHOR CONTRIBUTIONS

Design and development of the study: Thais P. Figueiredo; Rosymar C. de Lucas. Analysis of the results: Rodrigo A. Cazzaniga and Carolina N. França. Development of the manuscript: Fernando Segato, Rafael Taglialegna & Claudia M. L. Maffei.

REFERENCES

1. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within *Cryptococcus neoformans*? *FEMS Yeast Res*. 2006;6:574-87.

2. Lin X, Heitman J. The biology of the *Cryptococcus neoformans* species complex. *Annu Rev Microbiol*. 2006;60:69-105.

3. Romeo O, Scordino F, Chillemi V, Criseo G. *Cryptococcus neoformans*/*Cryptococcus gattii* species complex in southern Italy: an overview on the environmental diffusion of serotypes, genotypes and mating-types. *Mycopathologia*. 2012;174:283-91.

4. Hagen F, Khayhan K, Theelen B, Kolecka A, Polackek I, Sionov E, et al. Recognition of seven species in the *Cryptococcus gattii*/*Cryptococcus neoformans* species complex. *Fungal Genet Biol*. 2015;78:16-48.

5. Idnurm A, Lin X. Rising to the challenge of multiple *Cryptococcus* species and the diseases they cause. *Fungal Genet Biol*. 2015;78:1-6.

6. Feder V, Kmetzsch L, Staats CC, Vidal-Figueiredo N, Ligabue-Braun R, Carlini CR, et al. *Cryptococcus gattii* urease as a virulence factor and the relevance of enzymatic activity in cryptococcosis pathogenesis. *FEBS J*. 2015;282:1406-18.

7. Calvo BM, Colombo AL, Fischman O, Santiago A, Thompson L, Lazera M, et al. Antifungal susceptibilities varieties and electrophoretic karyotypes of clinical isolates of *Cryptococcus neoformans* from Brazil, Chile and Venezuela. *J Clin Microbiol*. 2001;39:2348-50.

8. Halliday CL, Bui T, Krockenberger M, Malik R, Ellis DH, Carter DA. Presence of α and a mating types in environmental and clinical collections of *Cryptococcus neoformans* var. *gattii* strains from Australia. *J Clin Microbiol*. 1999;37:2920-6.

9. Almeida F, Wolf JM, Casadevall A. Virulence-associated enzymes of *Cryptococcus neoformans*. *Eukaryot Cell*. 2015;14:1173-85.

10. Kwon-Chung KJ, Polackek I, Benett JE. Improved diagnostic medium for separation of *Cryptococcus neoformans* var. *neoformans* (serotypes A and D) and *Cryptococcus neoformans* var. *gattii* (serotypes B and C). *J Clin Microbiol*. 1982;15:535-7.

11. Wickes BL. The role of mating type and morphology in *Cryptococcus neoformans* pathogenesis. *Int J Med Microbiol*. 2002;292:313-29.

12. Wang L, Lin X. Mechanisms of unisexual mating in *Cryptococcus neoformans*. *Fungal Genet Biol*. 2011;48:651-60.

13. Davidson RC, Nichols CB, Cox GM, Perfect JR, Heitman J. A MAP KINASE cascade composed of cell type specific and non-specific elements controls mating and differentiation of the fungal pathogen *Cryptococcus neoformans*. *Mol Microbiol*. 2003; 49:469-85.

14. Jones SK Jr, Bennett RJ. Fungal mating pheromones: choreographing the dating. *Fungal Genet Biol*. 2011;48:668-76.

15. Sun S, Hsueh YP, Heitman J. Gene conversion occurs within the mating-type locus of *Cryptococcus neoformans* during sexual reproduction. *PLoS Genet*. 2012;8:e1002810.

16. Lengeler KB, Cox GM, Heitman J. Serotype AD strains of *Cryptococcus neoformans* are diploid or aneuploid and are heterozygous at the mating-type locus. *Infect Immun*. 2001; 69:115-22.

17. Chaturvedi S, Rodeghier B, Fan J, McClelland CM, Wickes BL, Chaturvedi V. Direct PCR of *Cryptococcus neoformans* MAT α and MATa pheromones to determine mating type, ploidy, and variety: a tool for epidemiological and molecular pathogenesis studies. *J Clin Microbiol*. 2000;3:2007-9.

18. Fraser JA, Subaran RL, Nichols CB, Heitman J. Recapitulation of the sexual cycle of the primary fungal pathogen *Cryptococcus neoformans* var. *gattii*: implications for an outbreak on Vancouver island, Canada. *Eukaryot Cell*. 2003;2:1036-45.

19. Escandón PQ, Quintero E, Granados D, Huérfano S, Castañeda E R. Isolation of *Cryptococcus gattii* serotype B from detritus of eucalyptus trees in Colombia. *Biomedica*. 2005;25:390-7.

20. D'Souza CA, Hagen F, Boekhout T, Cox GM, Heitman J. Investigation of the basis of virulence in serotype A strains of *Cryptococcus neoformans* from apparently immunocompetent individuals. *Curr. Genet*. 2004;46:92-102.
21. Horta JA, Staats CC, Casali AK, Ribeiro ÂM, Schrank IS, Schrank A, Vainstein MH. Epidemiological aspects of clinical and environmental *Cryptococcus neoformans* isolates in the Brazilian state Rio Grande do Sul. *Med Mycol*. 2002;40:565-71.
22. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, Chretien F, et al. Cryptococcal cell morphology affects host cell interactions and pathogenicity. *PLoS Pathog*. 2010;6:1-15.
23. Park SH, Choi SC, Lee KW, Kim MN, Hwang SM. Genotypes of clinical and environmental isolates of *Cryptococcus neoformans* and *Cryptococcus gattii* in Korea. *Mycobiology*. 2015;43:360-5.
24. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. *J Antimicrob Chemother*. 2013;68:2435-44.
25. Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, et al. *Cryptococcus neoformans*-*Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. *Antimicrob Agents Chemother*. 2012;56:5898-906.
26. Lacaz CS, Porto E, Martins JEC, Heins-Vaccari EM, Takahashi de Melo N. Tratado de micologia médica. 9 ed. São Paulo: Savier; 2002.
27. Bolano A, Stinchi S, Preziosi R, Bistoni F, Allegrucci M, Baldelli F, Martini A, Cardinali G. Rapid methods to extract DNA and RNA from *Cryptococcus neoformans*. *FEMS Yeast Res*. 2001;1:221-4.
28. Okabayashi K, Kano R, Watanabe T, Hasegawa A. Serotypes and mating types of clinical isolates from feline Cryptococcosis in Japan. *J Vet Med Sci*. 2006;68:91-4.
29. Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001.
30. Meyer W, Mitchell TG, Freedman EZ, Vilgalys R. Hybridization probes for conventional DNA fingerprinting used as single primers in the polymerase chain reaction to distinguish strains of *Cryptococcus neoformans*. *J Clin Microbiol*. 1993;31:2274-80.
31. Meyer W, Marszewska K, Amirmostofian M, Igreja RP, Hardtke C, Methling K, et al. Molecular typing of global isolates of *Cryptococcus neoformans* var. *neoformans* by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA—a pilot study to standardize techniques on which to base a detailed epidemiological survey. *Electrophoresis*. 1999;20:1790-9.
32. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, IberoAmerican Cryptococcal Study Group. Molecular typing of IberoAmerican *Cryptococcus neoformans* isolates. *Emerg Infect Dis*. 2003;9:189-95.
33. Chen YC, Chang TY, Liu JW, Chen FJ, Chien CC, Lee CH, et al. Increasing trend of fluconazole-non-susceptible *Cryptococcus neoformans* in patients with invasive cryptococcosis: a 12-year longitudinal study. *BMC Infect Dis*. 2015;15:277.
34. Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki LH, Alhadab AA, et al. Increased antifungal drug resistance in clinical isolates of *Cryptococcus neoformans* in Uganda. *Antimicrob Agents Chemother*. 2015;59:7197-204.
35. McClelland CM, Chang YC, Varma A, Kwon-Chung KJ. Uniqueness of the mating system in *Cryptococcus neoformans*. *Trends in Microbiology*. 2004;12:208-12.
36. Melo NT, Lacaz CS, Charbel CE, Pereira AD, Heins-Vaccari EM, Franca-Netto AS, et al. Quimiotipagem do *Cryptococcus neoformans*. Revisão da literatura. Novos dados epidemiológicos sobre a criptococose. Nossa experiência com o emprego do meio de C.G.B. no estudo daquela levedura. *Rev Inst Med Trop Sao Paulo*. 1993;35:469-78.
37. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS: 100 years after the discovery of *Cryptococcus neoformans*. *Clin Microbiol Rev*. 1995;8:515-48.
38. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Global trends in the antifungal susceptibility of *Cryptococcus neoformans* (1990 to 2004). *J Clin Microbiol*. 2005;43:2163-7.
39. Sorrel TC. *Cryptococcus neoformans* variety *gattii*. *Med Mycol*. 2001;39:155-68.
40. Fernandes FLO, Passos XS, Souza LK, Miranda AT, Cerqueira CH, Silva MR. *In vitro* susceptibility characteristics of *Cryptococcus neoformans* varieties from AIDS patients in Goiania, Brazil. *Mem Inst Oswaldo Cruz*. 2003;98:839-41.
41. Tay ST, Haryanty TT, NG KP, Rohani MY, Hamimah H. *In vitro* susceptibility of Malaysian clinical isolates of *Cryptococcus neoformans* var. *grubii* and *Cryptococcus gattii* to five antifungal drugs. *Mycoses*. 2006;49:324-30.
42. Tewari A, Behera B, Mathur P, Xess I. Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of *Cryptococcus neoformans*. *Mycopathologia*. 2012;173(5-6):427-33.
43. Bejar V, Tello M, García R, Guevara JM, Gonzales S, Vergaray G, et al. Molecular characterization and antifungal susceptibility of *Cryptococcus neoformans* strains collected from a single institution in Lima, Peru. *Rev Iberoam Micol*. 2015;32:88-92.
44. Mihara T, Izumikawa K, Takeya H, Ngamskulrunroj P, Umeyama T, Takazono T, et al. Multilocus sequence typing of *Cryptococcus neoformans* in non-HIV associated cryptococcosis in Nagasaki, Japan. *Med Mycol*. 2013;51:252-60.
45. Barreto de Oliveira MT, Boekhout T, Theelen B, Hagen F, Baroni FA, Lazera MS, et al. *Cryptococcus neoformans* shows a remarkable genotypic diversity in Brazil. *J Clin Microbiol*. 2004;42:1356-9.
46. Yan Z, Li X, Xu J. Geographic distribution of mating type alleles of *Cryptococcus neoformans* in four areas of the United States. *J Clin Microbiol*. 2002;40:965-72.
47. Keller SM, Viviani MA, Esposto MC, Cogliati M, Wickes BL. Molecular and genetic characterization of a serotype A MATa *Cryptococcus neoformans* isolates. *Microbiology*. 2003;149:131-42.
48. Barchiesi F, Cogliati M, Esposto MC, Spreghini E, Schimizzi AM, Wickes BL, et al. Comparative analysis of pathogenicity of *Cryptococcus neoformans* serotypes A, D and AD in murine cryptococcosis. *J Infect*. 2005;51:10-6.
49. Mlinaric-Missoni E, Hagen F, Chew WH, Vazic-Babic V, Boekhout T, Begovac J. *In vitro* antifungal susceptibilities and molecular typing of sequentially isolated clinical *Cryptococcus neoformans* strains from Croatia. *J Med Microbiol* 2011;60:1487-95.
50. Sullivan D, Haynes K, Moran G, Shanley D, Coleman D. Persistence, replacement, and microevolution of *Cryptococcus neoformans* strains in recurrent meningitis in AIDS patients. *J Clin Microbiol*. 1996;34:1739-44.
51. Liaw SJ, Wu HC, Hsueh PR. Microbiological characteristics of clinical isolates of *Cryptococcus neoformans* in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility. *Clin Microbiol Infect*. 2010;16:696-703.
52. Bertout S, Drakulovski P, Kouanfack C, Krasteva D, Ngouana T, Dunyach-Rémy C, et al. Genotyping and antifungal susceptibility testing of *Cryptococcus neoformans* isolates from Cameroonian HIV-positive adult patients. *Clin Microbiol Infect*. 2013;19:763-9.
53. Wu SY, Lei Y, Kang M, Xiao YL, Chen ZX. Molecular characterisation of clinical *Cryptococcus neoformans* and *Cryptococcus gattii* isolates from Sichuan province, China. *Mycoses*. 2015;58:280-7.
54. Kangogo M, Bader O, Boga H, Wanyoike W, Folba C, Worasilchai N, et al. Molecular types of *Cryptococcus gattii*/*Cryptococcus neoformans* species complex from clinical and environmental sources in Nairobi, Kenya. *Mycoses*. 2015;58:665-70.

55. Brito-Santos F, Barbosa GG, Trilles L, Nishikawa MM, Wanke B, Meyer W, et al. Environmental isolation of *Cryptococcus gattii* VGII from indoor dust from typical wooden houses in the deep Amazonas of the Rio Negro basin. PLoS One. 2015;10:e0115866.
56. Illnait-Zaragozi MT, Martínez-Machín GF, Fernández-Andreu CM, Perurena-Lancha MR, Hagen F, Meis JF. Cryptococcus and cryptococcosis in Cuba. A minireview. Mycoses. 2014;57:707-17.
57. Chen Y, Litvintseva AP, Frazzitta AE, Haverkamp MR, Wang L, Fang C, et al. Comparative analyses of clinical and environmental populations of *Cryptococcus neoformans* in Botswana. Mol Ecol. 2015;24:3559-71.
58. Badali H, Alian S, Fakhim H, Falahatinejad M, Moradi A, Mohammad Davoudi M, et al. Cryptococcal meningitis due to *Cryptococcus neoformans* genotype AFLP1/VNI in Iran: a review of the literature. Mycoses. 2015;58:689-93.
59. González GM, Casillas-Veja N, Garza-González E, Hernández-Bello R, Rivera G, Rodríguez JA, et al. Molecular typing of clinical isolates of *Cryptococcus neoformans*/*Cryptococcus gattii* species complex from Northeast Mexico. Folia Microbiol (Praha). 2016;61:51-6.
60. Dou HT, Xu YC, Wang HZ, Li TS. Molecular epidemiology of *Cryptococcus neoformans* and *Cryptococcus gattii* in China between 2007 and 2013 using multilocus sequence typing and the DiversiLab system. Eur J Clin Microbiol Infect Dis. 2015;34:753-62.
61. Souza LK, Fernandes Ode F, Kobayashi CC, Passos, XS, Costa CR, Lemos JA, et al. Antifungal susceptibilities of clinical and environmental isolates of *Cryptococcus neoformans* in Goiania city, Brazil. Rev Inst Med Trop. Sao Paulo. 2005;47:253-6.

Received: 14 October 2015

Accepted: 26 April 2016